535 related articles for article (PubMed ID: 18818309)
1. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Liakou CI; Kamat A; Tang DN; Chen H; Sun J; Troncoso P; Logothetis C; Sharma P
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14987-92. PubMed ID: 18818309
[TBL] [Abstract][Full Text] [Related]
2. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Carthon BC; Wolchok JD; Yuan J; Kamat A; Ng Tang DS; Sun J; Ku G; Troncoso P; Logothetis CJ; Allison JP; Sharma P
Clin Cancer Res; 2010 May; 16(10):2861-71. PubMed ID: 20460488
[TBL] [Abstract][Full Text] [Related]
3. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Chen H; Liakou CI; Kamat A; Pettaway C; Ward JF; Tang DN; Sun J; Jungbluth AA; Troncoso P; Logothetis C; Sharma P
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2729-34. PubMed ID: 19202079
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
[TBL] [Abstract][Full Text] [Related]
5. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
[TBL] [Abstract][Full Text] [Related]
6. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
Chen H; Fu T; Suh WK; Tsavachidou D; Wen S; Gao J; Ng Tang D; He Q; Sun J; Sharma P
Cancer Immunol Res; 2014 Feb; 2(2):167-76. PubMed ID: 24778280
[TBL] [Abstract][Full Text] [Related]
7. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.
Ng Tang D; Shen Y; Sun J; Wen S; Wolchok JD; Yuan J; Allison JP; Sharma P
Cancer Immunol Res; 2013 Oct; 1(4):229-34. PubMed ID: 24777852
[TBL] [Abstract][Full Text] [Related]
8. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
Hodi FS; Butler M; Oble DA; Seiden MV; Haluska FG; Kruse A; Macrae S; Nelson M; Canning C; Lowy I; Korman A; Lautz D; Russell S; Jaklitsch MT; Ramaiya N; Chen TC; Neuberg D; Allison JP; Mihm MC; Dranoff G
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3005-10. PubMed ID: 18287062
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
[TBL] [Abstract][Full Text] [Related]
10. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
Callahan MK; Wolchok JD; Allison JP
Semin Oncol; 2010 Oct; 37(5):473-84. PubMed ID: 21074063
[TBL] [Abstract][Full Text] [Related]
11. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy.
Sun J; Schiffman J; Raghunath A; Ng Tang D; Chen H; Sharma P
Cancer Immun; 2008 May; 8():9. PubMed ID: 18503261
[TBL] [Abstract][Full Text] [Related]
12. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
[TBL] [Abstract][Full Text] [Related]
13. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice.
Li J; Semple K; Suh WK; Liu C; Chen F; Blazar BR; Yu XZ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):962-9. PubMed ID: 21447398
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
15. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Vonderheide RH; LoRusso PM; Khalil M; Gartner EM; Khaira D; Soulieres D; Dorazio P; Trosko JA; Rüter J; Mariani GL; Usari T; Domchek SM
Clin Cancer Res; 2010 Jul; 16(13):3485-94. PubMed ID: 20479064
[TBL] [Abstract][Full Text] [Related]
16. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis.
Coquerelle C; Oldenhove G; Acolty V; Denoeud J; Vansanten G; Verdebout JM; Mellor A; Bluestone JA; Moser M
Gut; 2009 Oct; 58(10):1363-73. PubMed ID: 19505881
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 antibody ipilimumab negatively affects CD4
Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
[TBL] [Abstract][Full Text] [Related]
18. Human T cell activation by costimulatory signal-deficient allogeneic cells induces inducible costimulator-expressing anergic T cells with regulatory cell activity.
Vermeiren J; Ceuppens JL; Van Ghelue M; Witters P; Bullens D; Mages HW; Kroczek RA; Van Gool SW
J Immunol; 2004 May; 172(9):5371-8. PubMed ID: 15100277
[TBL] [Abstract][Full Text] [Related]
19. Inducible costimulator protein controls the protective T cell response against Listeria monocytogenes.
Mittrücker HW; Kursar M; Köhler A; Yanagihara D; Yoshinaga SK; Kaufmann SH
J Immunol; 2002 Nov; 169(10):5813-7. PubMed ID: 12421962
[TBL] [Abstract][Full Text] [Related]
20. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
